Prescription of acetylcholinesterase inhibitors and memantine in the Canary Islands, comparison with the Spanish population
e202109125
Keywords:
Dementia, Drug prescriptions, Pharmacoepidemiology, Acetylcholinesterase inhibitors, MemantineAbstract
Background: In the Canary Islands the prescriptions billed to the National Health System are registered in a database (FarmaCanarias). The main objective was to estimate the consumption of Acetylcholinesterase inhibitors (IACE) and Memantine in Canary Islands and to compare with a Spanish sample from Pharmacoepidemiological Research Base in Primary Care (PRBPC) which is national in scope. As secondary we determined the percentage in treatment in the Spanish sample.
Methods: The prescriptions of IACE and / or memantine in 2017 were calculated as Defined Daily Doses per 100 habitants (DHD) in FarmaCanarias and PRBPC. The prescriptions in FarmaCanarias were disclosed by island and age groups were also compared. The percentage of cases in treatment was calculated in PRBPC from records with diagnosis of “dementia”. All the comparations were made by Pearson’s χ2.
Results: The prescription of IACE and Memantine was: 3.042% (95% CI; 3.039-3.045) and 1.584% (95% CI; 1.582-1.587) in The Canary islands, respectively and 2.545% (95% CI; 2.518-2.572) and 0.922% (95% CI; 0.906-0.938), in PRBPC (p<0.001). DHDs between islands were different, except in two (p<0.001) The distribution by age group between FarmaCanarias and PRBPC was hetereogeneous (p<0.001). The percentage of dementia cases in treatment in PRBPC was 45.51% (95% CI; 45.186-45.838).
Conclusions: The prescription of IACE and Memantine was higher in the Canary Islands, which added to the difference by age group, suggests epidemiological differences in dementia compared to the mainland. There is heterogeneity between islands that could be due to epidemiological factors, provider or the Public Health Service.
Downloads
References
Wolff JL, Boult C, Boyd C, Anderson G. Newly reported chronic conditions and onset of functional dependency. J Am Geriatr Soc. 2005 May;53(5):851–855.
Virués-Ortega J, de Pedro-Cuesta J, Vega S, Seijo-Martínez M, Saz P, Rodríguez F et al. Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain. Acta Neurol Scand. 2011 May;123(5):316–324.
de Pedro-Cuesta J, Virués-Ortega J, Vega S, Seijo-Martínez M, Saz P, Rodríguez F et al. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008. BMC Neurol. 2009 Oct;9:55.
Villarejo Galende A, Eimil Ortiz M, Llamas Velasco S, Llanero Luque M, López de Silanes de Miguel C, Prieto Jurczynska C. Report by the Spanish Foundation of the Brain on the social impact of Alzheimer disease and other types of dementia. Neurologia. 2017 Dec.
Cahill S. WHO’s global action plan on the public health response to dementia: some challenges and opportunities. Vol. 24, Aging & mental health. England; 2020. p. 197–199.
Sartor F, Walckiers D. Estimate of disease prevalence using drug consumption data. Am J Epidemiol. 1995 Apr;141(8):782–7.
Alvarez F. Farmacoepidemiología. Estudios de Utilización de Medicamentos. Parte 2: Revisión de trabajos publicados en España. Pharm Pract (Granada). 2004;2(4):290–216.
Serna Arnáiz MC, Galván Santiago L, Gascó Eguiluz E, Manrique Manrique M, Foix Oña MM, Martín Gracia E. [Estimate of hypothyroidism prevalence in Lleida, Spain, based on thyroid hormone prescription]. Rev Esp Salud Publica. 2003;77(3):405–410.
Arrieta FJ, Calvo MJ, Peréz A, Saavedra P, Cordobés FJ, Cabral R et al. [Prevalence and consumption of medication in diabetes mellitus in Madrid (1996-2002)]. Rev Clin Esp. 2006 Mar;206(3):117–121.
Rodríguez Ruiz P, Hernando Arizaleta L, Navarro Sánchez C. [Evaluation of the consumption of rifampicin as an indicator of the epidemiological situation concerning tuberculosis in the autonomous community of Murcia]. Gac Sanit. 1987;1(3):101–105.
Knight R, Khondoker M, Magill N, Stewart R, Landau S. A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia. Dement Geriatr Cogn Disord. 2018;45(3–4):131–151.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004 Dec;351(24):2509–2518.
Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123289.
Criado-Alvarez JJ, Romo Barrientos C. [Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer’s disease]. Neurologia. 2010 May;25(4):234–238.
de Hoyos-Alonso MC, Bonis J, Tapias-Merino E, Castell M V, Otero A. Estimated prevalence of dementia based on analysis of drug databases in the Region of Madrid (Spain). Neurologia. 2016;31(1):1–8.
Muros M, Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis. 1996 Mar;121(1):13–21.
Coley N, Hoevenaar-Blom MP, van Dalen J-W, Moll van Charante EP, Kivipelto M, Soininen H et al. Dementia risk scores as surrogate outcomes for lifestyle-based multidomain prevention trials-rationale, preliminary evidence and challenges. Alzheimers Dement. 2020 Aug.
Marcelino-Rodríguez I, Elosua R, Pérez M del CR, Fernández-Bergés D, Guembe MJ, Alonso TV et al. On the problem of type 2 diabetes-related mortality in the Canary Islands, Spain. The DARIOS Study. Diabetes Res Clin Pract. 2016 Jan;111:74–82.
Padilla Luz A, Reyes Rodríguez JF, Gómez Rodríguez de Acuña A, González Gómez CM, Álvarez Dorta I, Pérez Cánovas ME. Adecuación prescripción-indicación de citicolina en atención primaria. Semergen. 2015;41(4):199–205.
Maciá-Martínez M-A, Gil M, Huerta C, Martín-Merino E, Álvarez A, Bryant V et al. Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain. Pharmacoepidemiol Drug Saf. 2020; Oct;29(10):1236-1245. doi: 10.1002/pds.5006. Epub 2020 Apr 26. PMID: 32337840
Grau M, Elosua R, Cabrera de León A, Guembe MJ, Baena-Díez JM, Vega Alonso T et al. [Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study]. Rev Esp Cardiol. 2011 Apr;64(4):295–304.
Blanco-Reina E, Ariza-Zafra G, Ocaña-Riola R, León-Ortiz M. 2012 American Geriatrics Society Beers criteria: enhanced applicability for detecting potentially inappropriate medications in European older adults? A comparison with the Screening Tool of Older Person’s Potentially Inappropriate Prescriptions. J Am Geriatr Soc. 2014 Jul;62(7):1217–1223.
Marión Buen J, Peiró S, Márquez Calderón S, Meneu de Guillerna R. [Variations in medical practice: importance, causes, and implications]. Med Clin (Barc). 1998 Mar;110(10):382–390.
Abellán García, Antonio; Aceituno Nieto, Pilar, Pérez Díaz, Julio, Ramiro Fariñas, Diego, Ayala García, Alba y Pujol Rodríguez R (2019). “Un perfil de las personas mayores en España, 2019. Indicadores estadísticos básicos”. Madrid, Informes Envejecimiento en red nº 22, 38p.
Villar-Fernández I, Bjerrum L, Feja C, Rabanaque MJ. Variability in the prescription of cholinesterase inhibitors and memantine. Dement Geriatr Cogn Disord. 2009;28(4):373–379.
De Hoyos-Alonso MC, Tapias-Merino E, Meseguer Barros CM, Sánchez-Martínez M, Otero A. Consumption trends for specific drugs used to treat dementia in the region of Madrid (Spain) from 2002 to 2012. Neurologia. 2015 Sep;30(7):416–424.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Norberto Rodríguez-Espinosa, Magali González-Colaço Harmand, Francisco Miranda Saavedra, Manuel Ángel Galván González, Mercedes Plasencia Núñez, Ana María Aldea Perona, Carlos Boada
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
